Liposome-based drug co-delivery systems in cancer cells.
01 Feb 2017-Materials Science and Engineering: C (Mater Sci Eng C Mater Biol Appl)-Vol. 71, Iss: 71, pp 1327-1341
TL;DR: This review paper focuses on LCC strategies including co-delivery of: two chemotherapeutic drugs, chemtherapeutic agent with anti-cancer metals, and chemotherapedic agent with gene agents and ligand-targeted liposome for co-Delivery of chemotherAPEutic agents.
About: This article is published in Materials Science and Engineering: C.The article was published on 2017-02-01. It has received 229 citations till now. The article focuses on the topics: Combination chemotherapy & Targeted drug delivery.
Citations
More filters
01 Jan 2008
TL;DR: The recent achievement of oxaliplatin for the treatment of colon cancer should not belie the imbalance between a plethora of investigated complexes and a very small number of clinically approved platinum drugs.
Abstract: Triggered by the resounding success of cisplatin, the past decades have seen tremendous efforts to produce clinically beneficial analogues. The recent achievement of oxaliplatin for the treatment of colon cancer should, however, not belie the imbalance between a plethora of investigated complexes and a very small number of clinically approved platinum drugs. Strategies opening up new avenues are increasingly being sought using complexes of metals other than platinum such as ruthenium or gallium. Based on the chemical differences between these metals, the spectrum of molecular mechanisms of action and potential indications can be broadened substantially. Other approaches focus on complexes with tumour-targeting properties, thereby maximizing the impact on cancer cells and minimizing the problem of adverse side effects, and complexes with biologically active ligands.
698 citations
TL;DR: In this paper, the authors highlight the recent development of smart drug delivery systems for a number of smart nanocarriers, including liposomes, micelles, dendrimers, meso-porous silica nanoparticles, gold nanoparticles and carbon nanotubes.
576 citations
Cites background from "Liposome-based drug co-delivery sys..."
...In addition to delivering imaging agents together with chemotherapeutics, liposomes are promising in the co-delivery of two chemotherapeutic drugs, gene agents [57] with chemotherapeutics as well as chemotherapeutics with anticancer metals [58]....
[...]
TL;DR: The limitations and notable advances of aptamer selection are presented, and the different methods used in the kinetic characterization of aptamers are compared, to comprehensively review the current shortage and achievement ofaptamer-related technology.
Abstract: Aptamers are short DNA/RNA oligonucleotides capable of binding to target molecules with high affinity and specificity. The process of selecting an aptamer is called Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Thanks to the inherit merits, aptamers have been used in a wide range of applications, including disease diagnosis, targeted delivery agents and therapeutic uses. To date, great achievements regarding the selection, modifications and application of aptamers have been made. However, few aptamer-based products have already successfully entered into clinical and industrial use. Besides, it is still a challenge to obtain aptamers with high affinity in a more efficient way. Thus, it is important to comprehensively review the current shortage and achievement of aptamer-related technology. In this review, we first present the limitations and notable advances of aptamer selection. Then, we compare the different methods used in the kinetic characterization of aptamers. We also discuss the impetus and developments of the clinical application of aptamers.
267 citations
TL;DR: This Review demonstrates the emerging aptamer discovery technologies in developing advanced techniques for producing aptamers with high performance consistently and efficiently as well as requiring less cost and resources but offering a great chance of success.
Abstract: Aptamers are oligonucleotide sequences with a length of about 25-80 bases which have abilities to bind to specific target molecules that rival those of monoclonal antibodies. They are attracting great attention in diverse clinical translations on account of their various advantages, including prolonged storage life, little batch-to-batch differences, very low immunogenicity, and feasibility of chemical modifications for enhancing stability, prolonging the half-life in serum, and targeted delivery. In this Review, we demonstrate the emerging aptamer discovery technologies in developing advanced techniques for producing aptamers with high performance consistently and efficiently as well as requiring less cost and resources but offering a great chance of success. Further, the diverse modifications of aptamers for therapeutic applications including therapeutic agents, aptamer-drug conjugates, and targeted delivery materials are comprehensively summarized.
189 citations
TL;DR: An overview of the strategies used to chemically modify chitosan by introduction of sulfonate groups on chitOSan backbone is provided, focusing on various sulfonating or sulfating agents used and substitution regioselectivity, and highlights their applications in biomedical field.
129 citations
References
More filters
TL;DR: The arsenal of nanocarriers and molecules available for selective tumour targeting, and the challenges in cancer treatment are detailed and emphasized.
Abstract: Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.
7,443 citations
Journal Article•
TL;DR: I MicroRNAs (miRNAs) are an abundant class of small non-protein-coding RNAs that function as negative gene regulators as discussed by the authors, and have been shown to repress the expression of important cancer-related genes and might prove useful in the diagnosis and treatment of cancer.
Abstract: I MicroRNAs (miRNAs) are an abundant class of small non-protein-coding RNAs that function as negative gene regulators. They regulate diverse biological processes, and bioinformatic data indicates that each miRNA can control hundreds of gene targets, underscoring the potential influence of miRNAs on almost every genetic pathway. Recent evidence has shown that miRNA mutations or mis-expression correlate with various human cancers and indicates that miRNAs can function as tumour suppressors and oncogenes. miRNAs have been shown to repress the expression of important cancer-related genes and might prove useful in the diagnosis and treatment of cancer.
6,064 citations
TL;DR: Evidence has shown that miRNA mutations or mis-expression correlate with various human cancers and indicates that miRNAs can function as tumour suppressors and oncogenes.
Abstract: MicroRNAs (miRNAs) are an abundant class of small non-protein-coding RNAs that function as negative gene regulators They regulate diverse biological processes, and bioinformatic data indicates that each miRNA can control hundreds of gene targets, underscoring the potential influence of miRNAs on almost every genetic pathway Recent evidence has shown that miRNA mutations or mis-expression correlate with various human cancers and indicates that miRNAs can function as tumour suppressors and oncogenes miRNAs have been shown to repress the expression of important cancer-related genes and might prove useful in the diagnosis and treatment of cancer
5,693 citations
"Liposome-based drug co-delivery sys..." refers background in this paper
...transiently become sensitized to the anti-tumor drug, thereby overcoming multi-drug resistance [142-145]....
[...]
TL;DR: It is shown that siRNA expression mediated by this vector causes efficient and specific down-regulation of gene expression, resulting in functional inactivation of the targeted genes.
Abstract: Mammalian genetic approaches to study gene function have been hampered by the lack of tools to generate stable loss-of-function phenotypes efficiently. We report here a new vector system, named pSUPER, which directs the synthesis of small interfering RNAs (siRNAs) in mammalian cells. We show that siRNA expression mediated by this vector causes efficient and specific down-regulation of gene expression, resulting in functional inactivation of the targeted genes. Stable expression of siRNAs using this vector mediates persistent suppression of gene expression, allowing the analysis of loss-of-function phenotypes that develop over longer periods of time. Therefore, the pSUPER vector constitutes a new and powerful system to analyze gene function in a variety of mammalian cell types.
4,937 citations
"Liposome-based drug co-delivery sys..." refers background in this paper
...A shRNA is an artificial structure with a hairpin turn that is expressed in cells via plasmids or vectors (viral or bacterial) to silence a desired gene [153, 154]....
[...]
TL;DR: For further successful development of this field, promising trends must be identified and exploited, albeit with a clear understanding of the limitations of these approaches.
Abstract: Liposomes — microscopic phospholipid bubbles with a bilayered membrane structure — have received a lot of attention during the past 30 years as pharmaceutical carriers of great potential. More recently, many new developments have been seen in the area of liposomal drugs — from clinically approved products to new experimental applications, with gene delivery and cancer therapy still being the principal areas of interest. For further successful development of this field, promising trends must be identified and exploited, albeit with a clear understanding of the limitations of these approaches.
4,572 citations
"Liposome-based drug co-delivery sys..." refers background in this paper
...The polymer layer surrounding the outer of liposome prevents them from rapid clearance by the RES [45, 46]....
[...]
...These particles are natural to the RES, leading to longer circulation time [178-180]....
[...]
...Results suggested that the co-delivery of RES and PTX in a liposomal system may potentially improve the treatment of MDR cancers [91]....
[...]
...Meng et al. co-encapsulated RES along with PTX in a PEGylated liposome to construct a liposomal form of combination therapy for drug-resistant tumors....
[...]
...However, unmodified liposomes are rapidly cleared by phagocytic cells of the reticuloendothelial system (RES) in blood circulation....
[...]